跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 12 条关于
“OncoSignature”
全部
12
临床试验
1
药物
0
机构
1
资讯
10
去年
FDA Grants Breakthrough Device Designation to Acrivon's ACR-368 OncoSignature Test for Endometrial Cancer
去年
Acrivon Therapeutics Grants Equity Awards to Employees Under Nasdaq Rule 5635(c)(4)
去年
FDA Grants Breakthrough Device Status to Acrivon's AI-Powered Cancer Diagnostic Platform
2年前
Acrivon Therapeutics' ACR-368 Shows Promise in Endometrial Cancer; ACR-2316 Cleared for Phase 1 Trials
去年
Acrivon Therapeutics to Showcase AP3 Platform and Clinical Program Updates at Upcoming R&D Event
去年
Acrivon Therapeutics Appoints Renowned Oncologist Dr. Mansoor Raza Mirza as Chief Medical Officer to Lead Clinical Development
2年前
Acrivon's ACR-368 Shows Promise in Endometrial Cancer, ACR-2316 Advances to Clinic
7个月前
Acrivon Therapeutics Launches CLIA-Certified Laboratory to Advance Precision Medicine Development
去年
Acrivon Therapeutics Initiates Phase 1 Trial of WEE1/PKMYT1 Inhibitor ACR-2316 for Solid Tumors
3个月前
Acrivon Therapeutics Reports 44% Response Rate for CHK1/2 Inhibitor ACR-368 in Endometrial Cancer Phase II Trial